Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 851 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hormone Replacement Therapy (HRT) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine

NCT00956943
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Nicoderm CQ transdermal nicotine, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Not applicable Interventional

Smoking Interventions for Hospital Patients

NCT01177176
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Extended Care Management, Standard Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 14, 2026, 2:57 PM EDT
Active, not recruiting Not applicable Interventional

Financial Incentives for Smoking Treatment II

NCT03979885
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Cessation
Interventions
Smoking cessation counseling (Quitline), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), Financial incentives for smoking cessation, Financial incentives for use of evidence-based smoking cessation therapies
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

NCT00943111
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
Eliglustat tartrate, Imiglucerase
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 4 Interventional Results available

EASY: Extended Access to Sollpura Over Years

NCT02823964
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Jackson, Mississippi • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 14, 2026, 2:57 PM EDT
Withdrawn Phase 2 Interventional

Trifecta Research Study

NCT06810765
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma, Brain Injuries
Interventions
Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, 5-MeO-DMT
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Alpha-Galactosidase A Replacement Therapy for Fabry Disease

NCT00048906
View directory record Official record
Conditions
Fabry Disease
Interventions
DRX005B
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 2:57 PM EDT
Not listed Not applicable Interventional

Interactive Computer-adaptive Chronic Kidney Disease Education Program

NCT06364358
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension
Interventions
Computerized CKD Education, Usual Hospital Care
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 14, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional

Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy

NCT06948058
View directory record Official record
Conditions
Smoking Cessation, Obesity and Obesity-related Medical Conditions
Interventions
Electronic Cigarettes (EC), Nicotine replacement therapy (NRT)
Other
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

Financial Incentives for Smoking Cessation Among Mothers

NCT05740098
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Best Practices, Financial Incentives, Nicotine Replacement Therapy
Behavioral · Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

NCT00630747
View directory record Official record
Conditions
Hunter Syndrome, Mucopolysaccharidosis II (MPS II)
Interventions
Idursulfase
Biological
Lead sponsor
Shire
Industry
Eligibility
5 Years and older · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
16
States / cities
Phoenix, Arizona • Oakland, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Lozenges and Assisted Self-help for Smokeless Tobacco Cessation

NCT01341938
View directory record Official record
Conditions
Smokeless Tobacco Cessation
Interventions
Commit® nicotine lozenges (4 mg) & self-help materials, Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials, Phone counseling & self-help materials
Drug · Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 14, 2026, 2:57 PM EDT
Recruiting No phase listed Observational

Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients

NCT05988658
View directory record Official record
Conditions
Acute Kidney Injury, Biomarkers
Interventions
ESTOP - AKI 2.0
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03237065
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Muscle Shoals, Alabama • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 14, 2026, 2:57 PM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation

NCT01318811
View directory record Official record
Conditions
Acute Kidney Injury, Acute Renal Failure, Heart Failure
Interventions
Dilute unfractionated heparin, Standard concentration unfractionated heparin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 14, 2026, 2:57 PM EDT
Terminated Not applicable Interventional Results available

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

NCT01400893
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SCD
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

Intrathecal Enzyme Replacement for Hurler Syndrome

NCT00638547
View directory record Official record
Conditions
Hurler Syndrome
Interventions
IRT Laronidase
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
6 Months to 3 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking

NCT01359709
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Nicotine polacrilex
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 14, 2026, 2:57 PM EDT
Available No phase listed Expanded access

Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)

NCT07733856
View directory record Official record
Conditions
Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
Interventions
Tralesinidase alfa (TA)
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
12 Months and older
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Early Phase 1 Interventional

Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving

NCT01329614
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Cue Extinction Training, Nicotine Replacement Therapy, Cue Extinction Therapy, Progressive Muscle Relaxation
Behavioral · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing Genetic Education for Smoking Cessation

NCT01186016
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Genetic Education Session, Nutrition Education Session
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine

NCT01944423
View directory record Official record
Conditions
Nicotine Addiction, Panic Attack
Interventions
d-cycloserine, Pill Placebo, Nicotine replacement therapy, Panic and Smoking Reduction Treatment
Drug · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 14, 2026, 2:57 PM EDT
Recruiting No phase listed Observational

Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

NCT06184503
View directory record Official record
Conditions
Alpha-Mannosidosis
Interventions
Velmanase Alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Up to 3 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Miami, Florida • Greenwood, South Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 14, 2026, 2:57 PM EDT